BMJ  2008;336:1155 (24 May), doi:10.1136/bmj.39588.708125.DB

News

Cancer charity starts research programme with drug "borrowed" from industry

¹ London

The first 150 words of the full text of this article appear below.

The charity Cancer Research UK announced this week that it has started work on its first clinical research programme in a new partnership arrangement that enables it to "borrow" candidate drugs that have been shelved by drug companies so it can further explore their potential.

The cancer research charity and its commercial arm, Cancer Research Technology, is starting the programme with the clinical development of a tyrosine kinase inhibitor, AZD0424, provided by the drug company AstraZeneca.

Under the terms of the agreement, which is called a clinical development partnership, the charity will conduct early clinical trials at no cost to the company. If the drug looks promising, the company retains the option to develop and market the drug, but the charity will get a share of any resulting revenue (BMJ 2006;332:1112; doi:10.1136/bmj.332.7550.1112).

Dr Keith Blundy, chief executive of Cancer Research Technology (CRT), said: "The signing of our . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article

Cancer charity is to “borrow” candidate drugs shelved by companies

Susan Mayor
BMJ 2006 332: 1112. [Extract] [Full Text] [PDF]